Veldoreotide
- Generic Name
- Veldoreotide
- Drug Type
- Small Molecule
- Chemical Formula
- C60H74N12O10
- CAS Number
- 252845-37-7
- Unique Ingredient Identifier
- 1Z83587HBN
- Background
Somatoprim is under investigation for the treatment of Acromegaly.
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
Phase 1
- Conditions
- Breast CancerSkin DiseasesSkin Cancer
- Interventions
- Drug: Topical approved placebo
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 30
- Registration Number
- NCT04138342
- Locations
- 🇪🇬
Assiut Clinic, Assiut, Egypt
🇸🇦Faculty of Pharmacy, Buraidah, Qassim, Saudi Arabia
🇸🇦Pharmaceutics dept., Faculty of Pharmacy, Qassim University, Buraidah, Qassim, Saudi Arabia
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Aspireo Pharmaceuticals Limited
- Target Recruit Count
- 20
- Registration Number
- NCT02235987
Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Aspireo Pharmaceuticals Limited
- Target Recruit Count
- 8
- Registration Number
- NCT02217826
Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: DG3173+OctreotideDrug: DG3173 Placebo+Octreotide PlaceboDrug: DG3173 PlaceboDrug: Octreotide+DG3173 Placebo
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Aspireo Pharmaceuticals Limited
- Target Recruit Count
- 42
- Registration Number
- NCT02217839
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Aspireo Pharmaceuticals Limited
- Target Recruit Count
- 8
- Registration Number
- NCT02217800
Single Ascending Dose Tolerability Study of DG3173
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Aspireo Pharmaceuticals Limited
- Target Recruit Count
- 72
- Registration Number
- NCT02217488
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath